11,745 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Pitcairn Co.

Pitcairn Co. purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,745 shares of the biopharmaceutical company's stock, valued at approximately $354,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TGTX. Arizona State Retirement System raised its holdings in shares of TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. raised its holdings in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the period. Brookstone Capital Management lifted its position in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after buying an additional 624 shares in the last quarter. Daymark Wealth Partners LLC increased its position in shares of TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after acquiring an additional 689 shares in the last quarter. Finally, New York State Teachers Retirement System raised its stake in shares of TG Therapeutics by 1.9% in the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after acquiring an additional 837 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Up 2.0 %

TGTX stock traded up $0.73 during trading on Friday, reaching $36.71. The stock had a trading volume of 2,052,937 shares, compared to its average volume of 3,110,585. The firm has a fifty day moving average price of $35.76 and a 200 day moving average price of $31.39. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $5.77 billion, a P/E ratio of -367.06 and a beta of 2.14. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $43.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.